Opus Genetics awarded non-dilutive funding from the RD Fund

Opus Genetics (IRD) disclosed that the Retinal Degeneration Fund has entered into a funding agreement with Opus providing for up to $2M in non-dilutive funding intended to support the advancement of Opus’ OPGx-MERTK program to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosine kinase gene. With the addition of this funding, based on current projections, Opus believes that its cash on hand will now be sufficient to fund operations into the second half of 2026.